Glucocorticoid Effect
PreclinicalSmall molecule
Glucocorticoid Effect is one of 16 small molecule programs targeting Joint Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Joint Disease
#DrugCompanyPhaseTrials
1Firazyr
TakedaApproved
Humira
CCelltrion
Approved
Cyklokapron
AAmring
Approved
Nucynta
CCollegium Pharmaceutical, Inc.
Approved
Oxycontin
PProtega
Approved
Oxycodone CR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Oxycodone IR
Johnson & JohnsonPhase 3
Tapentadol ER
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Tapentadol IR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Joint Disease1 trial
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Recruiting·—··NCT06395883·160 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glucocorticoid Effect. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- DDiakonhjemmet Hospital